RU2707285C2 - Рапамицин для лечения лимфангиолейомиоматоза - Google Patents

Рапамицин для лечения лимфангиолейомиоматоза Download PDF

Info

Publication number
RU2707285C2
RU2707285C2 RU2016117764A RU2016117764A RU2707285C2 RU 2707285 C2 RU2707285 C2 RU 2707285C2 RU 2016117764 A RU2016117764 A RU 2016117764A RU 2016117764 A RU2016117764 A RU 2016117764A RU 2707285 C2 RU2707285 C2 RU 2707285C2
Authority
RU
Russia
Prior art keywords
rapamycin
composition
particles
drug
composition according
Prior art date
Application number
RU2016117764A
Other languages
English (en)
Russian (ru)
Other versions
RU2016117764A (ru
RU2016117764A3 (https=
Inventor
М. РОТБЕРГ Джонатан
Хенри ЛИХЕНШТЕЙН
Томас АРМЕР
Мл. МЕЛВИН Лоуренс С.
Original Assignee
ЭйАй ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйАй ТЕРАПЬЮТИКС, ИНК. filed Critical ЭйАй ТЕРАПЬЮТИКС, ИНК.
Publication of RU2016117764A publication Critical patent/RU2016117764A/ru
Publication of RU2016117764A3 publication Critical patent/RU2016117764A3/ru
Application granted granted Critical
Publication of RU2707285C2 publication Critical patent/RU2707285C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016117764A 2013-10-08 2014-10-07 Рапамицин для лечения лимфангиолейомиоматоза RU2707285C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888066P 2013-10-08 2013-10-08
US61/888,066 2013-10-08
PCT/US2014/059529 WO2015054280A1 (en) 2013-10-08 2014-10-07 Rapamycin for the treatment of lymphangioleiomyomatosis

Publications (3)

Publication Number Publication Date
RU2016117764A RU2016117764A (ru) 2017-11-17
RU2016117764A3 RU2016117764A3 (https=) 2018-06-05
RU2707285C2 true RU2707285C2 (ru) 2019-11-26

Family

ID=52813582

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016117764A RU2707285C2 (ru) 2013-10-08 2014-10-07 Рапамицин для лечения лимфангиолейомиоматоза

Country Status (11)

Country Link
US (4) US10307370B2 (https=)
EP (2) EP3738592B1 (https=)
JP (2) JP6529012B2 (https=)
KR (1) KR102256576B1 (https=)
CN (2) CN113768881A (https=)
AU (1) AU2014332080B2 (https=)
CA (1) CA2926719C (https=)
IL (1) IL244909B (https=)
MX (1) MX381173B (https=)
RU (1) RU2707285C2 (https=)
WO (1) WO2015054280A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
KR20160120739A (ko) * 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
DK3125875T3 (da) * 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
KR20170095807A (ko) * 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
MA40910A (fr) * 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) * 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
DK3506899T3 (da) * 2016-08-31 2022-03-07 Childrens Hospital Philadelphia Præparater og fremgangsmåder til diagnosticering og behandling af lymfesystemlidelser
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US20200230115A1 (en) * 2017-07-24 2020-07-23 University Of Cincinnati Methods of treating influenza-associated viral pneumonia
US20190105460A1 (en) 2017-09-11 2019-04-11 Sensory Cloud, Llc Compositions, systems, methods, and articles for retro-nasal delivery
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3846825A4 (en) 2018-09-05 2022-11-02 Sensory Cloud, LLC FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES
WO2023196676A1 (en) * 2022-04-09 2023-10-12 The Brigham And Women's Hospital, Inc. Treating tuberous sclerosis complex-associated diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478578A (en) * 1991-12-10 1995-12-26 Boehringer Ingelheim Kg Powders for inhalation
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20080127972A1 (en) * 2004-11-23 2008-06-05 Vectura Limited Dry Powder Inhaler Formulations Comprising Surface-Modified Particles With Anti-Adherent Additives
RU2355399C2 (ru) * 2003-03-05 2009-05-20 Уайт Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
RU2478387C2 (ru) * 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517482A (en) 1949-04-09 1950-08-01 Sharp & Dohme Inc Inhaler
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE3345722A1 (de) * 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
AU688782B2 (en) 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
PL319600A1 (en) 1994-09-29 1997-08-18 Andaris Ltd Spray-dried microparticles as therapeutic carriers
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
DE19523516C1 (de) 1995-06-30 1996-10-31 Asta Medica Ag Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
EP0954283B1 (en) 1996-12-30 2007-03-21 Battelle Memorial Institute Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
CA2457148A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
JP2005502653A (ja) 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
AU2003269989B8 (en) 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
CN103405405A (zh) * 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
AR043504A1 (es) 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
FR2882366B1 (fr) 2005-02-18 2008-04-18 Coletica Sa Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols
JP2008531686A (ja) 2005-03-02 2008-08-14 ワイス ラパマイシンの精製
AU2006222409A1 (en) 2005-03-08 2006-09-14 Lifecycle Pharma A/S Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
US20060210638A1 (en) 2005-03-17 2006-09-21 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
CN1883474A (zh) 2005-06-22 2006-12-27 华北制药集团新药研究开发有限责任公司 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物
US7446096B2 (en) 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
RU2008121713A (ru) 2005-12-20 2010-01-27 Вайет (Us) Контроль стабильности лекарственной формы cci-779 посредством контроля примесей лекарственныхого вещества
LT1983984T (lt) 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
AU2006350684B2 (en) 2006-11-10 2012-07-05 Biocon Limited A pure form of rapamycin and a process for recovery and purification thereof
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2092942A1 (en) 2006-11-20 2009-08-26 Lutonix, Inc. Drug releasing coatings for medical devices
EP1938800A1 (en) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
NO2252275T3 (https=) * 2008-02-13 2018-04-28
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
CN102292072A (zh) 2009-01-26 2011-12-21 特瓦制药工业有限公司 用微粒包衣载体的方法
US20100196483A1 (en) 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
GB0905818D0 (en) 2009-04-06 2009-05-20 Airbus Uk Ltd Coupling assembly
AU2010233073B2 (en) 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
US9248110B2 (en) 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
WO2011163600A2 (en) 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration
US20140037548A1 (en) 2010-06-28 2014-02-06 The Board Of Trustees Of The Leland Standford Junior University Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
CA2812952A1 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
CN102670518B (zh) 2011-03-14 2014-08-20 齐鲁制药有限公司 一种难溶性药物球形颗粒的制备方法
US20140067548A1 (en) 2012-08-31 2014-03-06 Sap Ag Saving on device functionality for business calendar
CN112075911A (zh) 2013-03-28 2020-12-15 恩多巧爱思股份有限公司 紧凑的多观察元件内窥镜系统
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
KR20160120739A (ko) * 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
DK3125875T3 (da) 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DE102014005466A1 (de) 2014-04-12 2015-10-15 Klaus Düring Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN108039392A (zh) 2017-11-06 2018-05-15 北京汉能薄膜发电技术有限公司 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法
US11123789B2 (en) 2019-01-22 2021-09-21 Lift Technology Method for inorganic binder castings

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478578A (en) * 1991-12-10 1995-12-26 Boehringer Ingelheim Kg Powders for inhalation
RU2355399C2 (ru) * 2003-03-05 2009-05-20 Уайт Противоопухолевые композиции, содержащие производное рапамицина и ингибитор ароматазы
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20080127972A1 (en) * 2004-11-23 2008-06-05 Vectura Limited Dry Powder Inhaler Formulations Comprising Surface-Modified Particles With Anti-Adherent Additives
RU2478387C2 (ru) * 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension

Also Published As

Publication number Publication date
EP3054948A1 (en) 2016-08-17
CA2926719C (en) 2020-11-24
MX381173B (es) 2025-03-12
RU2016117764A (ru) 2017-11-17
EP3738592B1 (en) 2022-01-26
KR102256576B1 (ko) 2021-05-27
CN113768881A (zh) 2021-12-10
US20230355516A1 (en) 2023-11-09
IL244909A0 (en) 2016-05-31
IL244909B (en) 2020-05-31
RU2016117764A3 (https=) 2018-06-05
CA2926719A1 (en) 2015-04-16
JP6799108B2 (ja) 2020-12-09
US20160235668A1 (en) 2016-08-18
JP6529012B2 (ja) 2019-06-12
US11123289B2 (en) 2021-09-21
US20220054410A1 (en) 2022-02-24
US20200276120A1 (en) 2020-09-03
WO2015054280A1 (en) 2015-04-16
US12171874B2 (en) 2024-12-24
AU2014332080B2 (en) 2020-02-27
JP2019151649A (ja) 2019-09-12
US11744797B2 (en) 2023-09-05
EP3738592A1 (en) 2020-11-18
KR20160088300A (ko) 2016-07-25
MX2016004530A (es) 2017-02-13
CN106061482A (zh) 2016-10-26
EP3054948A4 (en) 2017-04-19
EP3054948B1 (en) 2020-08-12
US10307370B2 (en) 2019-06-04
NZ718717A (en) 2021-06-25
JP2016532672A (ja) 2016-10-20

Similar Documents

Publication Publication Date Title
US12171874B2 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
US11491143B2 (en) Inhalable rapamycin formulation for the treatment of pulmonary hypertension
US20150265582A1 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
AU2014332080A1 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
WO2016130645A1 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
HK40040785A (en) Rapamycin for the treatment of lymphangioleiomyomatosis
HK40040785B (en) Rapamycin for the treatment of lymphangioleiomyomatosis
HK1227315A1 (en) Rapamycin for the treatment of lymphangioleiomyomatosis
HK1227315B (en) Rapamycin for the treatment of lymphangioleiomyomatosis
NZ718717B2 (en) Rapamycin for the treatment of lymphangioleiomyomatosis

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant